Alar Competitors

Stocks . Taiwan . 
Stock . Alar Pharmaceuticals
6785 Stock  TWD 251.50  4.00  1.57%   
Alar Pharmaceuticals competes with DV Biomed, GeneFerm Biotechnology, CTCI Corp, Ennoconn Corp, and Chong Hong; as well as few others. The company operates under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. Analyzing Alar Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Alar Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Alar Pharmaceuticals Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Alar Pharmaceuticals competition on your existing holdings.
  
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Alar Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
252.17255.50258.83
Details
Intrinsic
Valuation
LowRealHigh
229.95275.31278.64
Details

Alar Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Alar Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Alar and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Alar Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
2485
+ 0.79
1796
8045
+ 0.66
6414
8432
+ 0.6
6539
2412
+ 0.57
2485
2412
+ 0.52
1796
9933
+ 0.51
6539
  
High negative correlations   
5534
- 0.71
6414
8045
- 0.7
5534
5534
- 0.51
1796
8045
- 0.39
8432
2485
- 0.36
5534
8432
- 0.29
6414

Risk-Adjusted Indicators

There is a big difference between Alar Stock performing well and Alar Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Alar Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
6539  1.56  0.30  0.18 (22.56) 1.31 
(2.14)
 3.89 
(2.59)
 13.13 
1796  1.57  0.16  0.07  5.73  2.28 
(1.46)
 5.10 
(4.82)
 15.51 
9933  1.17  0.17  0.08 (2.36) 2.12 
(1.20)
 2.52 
(2.06)
 12.99 
6414  1.46 (0.02) 0.00  0.25  0.00 
 0.00 
 3.06 
(2.75)
 9.06 
5534  2.39  0.47  0.16  0.95  2.64 
(2.53)
 5.43 
(4.40)
 16.20 
2485  1.09  0.00  0.02 (0.03) 1.33 
(1.14)
 2.38 
(2.44)
 7.16 
2712  0.96 (0.09) 0.00  0.38  0.00 
 0.00 
 2.04 
(2.45)
 7.13 
2412  0.56 (0.02) 0.00 (0.14) 0.00 
 0.00 
 1.20 
(1.18)
 3.61 
8432  1.85  0.31  0.14  0.23  1.98 
(2.08)
 4.19 
(2.82)
 12.50 
8045  2.88 (0.14) 0.00 (0.57) 0.00 
 0.00 
 7.56 
(4.66)
 17.12 
All Fundamental Data

Alar Pharmaceuticals Competitive Analysis

The better you understand Alar Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Alar Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Alar Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
6785 6539 1796 9933 6414 5534 2485 2712 2412 8432
 1.57 
 251.50 
Alar
 3.89 
 147.20 
6539
 2.26 
 65.00 
GeneFerm
 0.38 
 53.40 
CTCI
 1.95 
 327.50 
Ennoconn
 0.86 
 115.00 
Chong
 1.64 
 21.75 
Zinwell
 0.66 
 30.00 
FarGlory
 0.79 
 125.50 
Chunghwa
 1.02 
 69.20 
Tsh
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
OK
Insignificant
OK
Very Weak
OK
Insignificant
Very Weak
Very Weak
OK
Odds of Financial Distress
(Probability Of Bankruptcy)
Below Average
Low
Low
Low
Low
Low
Below Average
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Fairly Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Hold
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Strong Hold
Strong Sell
Strong Sell
Hold
Strong Buy
Current Ratio
97.77
2.32
1.98
1.12
1.38
3.0
3.45
0.24
1.66
5.36
Net Asset
N/A
N/A
1.32 B
87.42 B
100.63 B
41.73 B
8.56 B
1.45 B
513.07 B
1.17 B
Profit Margin
N/A
16.64
0.15
0.0274
0.0169
0.32
-0.0202
0.013
0.17
0.15
EBITDA
(100.27 M)
448.99 M
123.07 M
4.46 B
7.97 B
1.64 B
(146.92 M)
33.24 M
46.84 B
71.41 M
Current Valuation
2.47 B
3.68 B
2.48 B
25.43 B
45.69 B
38.19 B
5.26 B
3.63 B
875.55 B
1.17 B
Price To Book
4.97
3.33
2.94
1.93
1.66
1.1
0.97
2.88
2.34
1.77
Operating Margin
N/A
14.88
0.17
0.0386
0.0339
0.38
-0.0695
0.021
0.22
0.16
Retained Earnings
N/A
N/A
N/A
5.3 B
1.22 B
6.19 B
3.44 B
N/A
134.47 B
N/A
Current Asset
N/A
N/A
N/A
48.05 B
5.57 B
25.47 B
8.19 B
N/A
84.11 B
N/A
Five Year Return
N/A
N/A
N/A
5.36
2.3
7.65
4.39
2.67
4.72
3.54
Beta
N/A
0.48
0.89
0.22
1.22
0.32
0.69
-0.0252
0.0156
-0.0266
Number Of Employees
19
316
12
50
17
20
17
321
134
80
Shares Outstanding
57 M
59.26 M
41.46 M
784.39 M
106.04 M
290.33 M
317.69 M
105 M
7.76 B
38.4 M
Cash Flow From Operations
(71.85 M)
463.36 M
112.23 M
14.56 B
1.59 B
(4.38 B)
(560.2 M)
32.26 M
74.86 B
68.71 M
Annual Yield
N/A
N/A
0.0139
0.0508
0.0304
0.0591
0.0267
0.0209
0.0406
0.0319
Total Debt
1.07 M
249.93 M
31.25 M
15.02 B
16.8 B
N/A
5.51 M
35.7 M
28.58 B
7.01 M
Return On Equity
-10.38
23.52
0.12
0.18
0.14
0.17
-0.0268
0.0051
0.0942
0.0635
Z Score
N/A
9.6
61.8
1.2
0.6
N/A
N/A
59.4
18.0
N/A
Return On Asset
-10.09
8.85
0.0534
0.0255
0.0233
0.054
-0.0309
0.0039
0.0592
0.0387
Book Value Per Share
10.5
20.43
19.63
22.02
128.12
64.91
19.48
11.46
47.94
27.67
Current Liabilities
N/A
N/A
N/A
38.02 B
3.99 B
15.27 B
3.19 B
N/A
54.05 B
N/A
Total Asset
N/A
N/A
1.32 B
87.42 B
100.63 B
41.73 B
8.56 B
1.45 B
513.07 B
1.17 B
Debt To Equity
0.001
0.21
0.72
76.0
76.6
29.4
N/A
9.6
2.9
0.6
Last Dividend Paid
N/A
1.64
N/A
2.26
7.0
4.41
N/A
N/A
N/A
1.5
Target Price
N/A
N/A
N/A
53.5
240.29
86.3
40.9
N/A
112.2
N/A
Shares Owned By Institutions
N/A
N/A
N/A
19.08
13.32
16.7
4.33
2.68
24.38
N/A
Market Capitalization
2.98 B
4.03 B
3.22 B
34.91 B
24.28 B
21.72 B
5.69 B
3.54 B
884.35 B
1.78 B
Price To Earning
N/A
13.49
53.28
20.93
17.4
10.75
22.08
163.38
22.46
56.63
Price To Earnings To Growth
N/A
N/A
N/A
1.15
1.07
0.47
N/A
N/A
-45.87
N/A
Price To Sales
N/A
2.22
4.16
0.36
0.19
2.17
0.93
7.26
4.0
4.22
Net Income
(64.78 M)
301.4 M
57.41 M
1.64 B
1.33 B
1.28 B
(354.21 M)
(20.74 M)
36.52 B
47.11 M
Earnings Per Share
-2.86
5.04
2.18
3.24
14.2
10.43
-1.15
0.06
4.71
1.78
Shares Owned By Insiders
N/A
N/A
57.17
27.37
39.5
42.53
13.49
89.11
41.21
64.94
Revenue
600 K
1.81 B
522.33 M
70.54 B
96.56 B
4.85 B
6.28 B
350.97 M
216.74 B
413.48 M
Working Capital
N/A
N/A
N/A
10.03 B
1.58 B
10.2 B
5 B
N/A
30.06 B
N/A
Cash And Equivalents
556.12 M
538.29 M
619.1 M
18 B
12.85 B
2.16 B
1.57 B
22.42 M
43.02 B
708.28 M
Cash Per Share
9.76
9.14
15.32
23.62
155.03
7.43
4.94
0.21
5.55
18.36
Gross Profit
600 K
925.51 M
192.65 M
4 B
20.48 B
1.84 B
102.97 M
68.05 M
46.84 B
247.36 M
Day Typical Price
253.33
147.2
65.73
53.27
331.67
115.0
21.7
30.15
125.5
69.2
Accumulation Distribution
4336.38
N/A
5499.2
42434.81
121016.0
33980.16
51590.18
192.12
127416.0
2401.22
Market Facilitation Index
0.0
N/A
0.0
N/A
0.0
0.0
N/A
0.0
N/A
0.0
Daily Balance Of Power
(0.73)
9.2 T
(0.54)
0.25
(0.52)
(0.33)
0.7778
(0.44)
(1.00)
0.5833
Period Momentum Indicator
(4.00)
5.51
(1.50)
0.2
(6.50)
(1.00)
0.35
(0.20)
(1.00)
0.7
Rate Of Daily Change
0.98
1.04
0.98
1.0
0.98
0.99
1.02
0.99
0.99
1.01
Day Median Price
254.25
147.2
66.1
53.2
333.75
115.0
21.67
30.23
125.5
69.2
Price Action Indicator
(4.75)
2.75
(1.85)
0.3
(9.50)
(0.50)
0.25
(0.32)
(0.50)
0.35
Coefficient Of Variation
(1,678)
749.31
1587.12
981.98
(40,628)
672.64
10609.78
(1,810)
(4,663)
817.36
Mean Deviation
2.55
1.56
1.57
1.17
1.46
2.39
1.09
0.9634
0.563
1.85
Jensen Alpha
(0.22)
0.3042
0.1583
0.1736
(0.02)
0.4726
1.0E-4
(0.09)
(0.02)
0.3084
Total Risk Alpha
(0.07)
0.4021
0.2675
0.2509
0.0641
0.5907
0.0614
(0.03)
0.0043
0.374
Sortino Ratio
N/A
0.1842
0.0659
0.0849
N/A
0.161
0.0207
N/A
N/A
0.1404
Downside Variance
N/A
3.23
7.78
5.64
N/A
9.12
2.03
N/A
N/A
4.66
Standard Deviation
3.55
2.36
2.66
1.82
1.91
3.16
1.41
1.42
0.7204
2.35
Kurtosis
1.4
6.54
4.8
13.75
0.7452
0.6311
0.502
2.53
0.0274
0.3377
Potential Upside
7.79
3.89
5.1
2.52
3.06
5.43
2.38
2.04
1.2
4.19
Treynor Ratio
22.36
(22.56)
5.73
(2.36)
0.2465
0.9522
(0.03)
0.376
(0.14)
0.2309
Maximum Drawdown
16.79
13.13
15.51
12.99
9.06
16.2
7.16
7.13
3.61
12.5
Variance
12.58
5.56
7.07
3.32
3.63
9.99
1.98
2.01
0.5189
5.5
Market Risk Adjusted Performance
22.37
(22.55)
5.74
(2.35)
0.2565
0.9622
(0.02)
0.386
(0.13)
0.2409
Risk Adjusted Performance
(0.03)
0.0919
0.0476
0.0711
0.0051
0.1022
0.0115
(0.03)
(0.01)
0.0849
Skewness
1.12
1.88
1.11
(2.61)
0.3621
0.286
0.338
0.2907
0.3518
0.2404
Semi Deviation
N/A
1.31
2.28
2.12
N/A
2.64
1.33
N/A
N/A
1.98
Information Ratio
(0.06)
0.1403
0.0691
0.1107
0.0061
0.1538
0.021
(0.04)
0.0011
0.1293
Value At Risk
(4.56)
(2.59)
(4.82)
(2.06)
(2.75)
(4.40)
(2.44)
(2.45)
(1.18)
(2.82)
Expected Short fall
N/A
(2.14)
(1.46)
(1.20)
N/A
(2.53)
(1.14)
N/A
N/A
(2.08)
Downside Deviation
N/A
1.8
2.79
2.38
N/A
3.02
1.42
N/A
N/A
2.16
Semi Variance
N/A
1.73
5.18
4.48
N/A
6.95
1.77
N/A
N/A
3.93

Alar Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Alar Pharmaceuticals Competition

Alar Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Alar Pharmaceuticals in relation to its competition. Alar Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Alar Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Alar Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Alar Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Alar Pharmaceuticals position

In addition to having Alar Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Copper Thematic Idea Now

Copper
Copper Theme
Companies involved in production of copper. The Copper theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Copper Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Alar Stock Analysis

When running Alar Pharmaceuticals' price analysis, check to measure Alar Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alar Pharmaceuticals is operating at the current time. Most of Alar Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alar Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alar Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alar Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY